PHPeishan Hu

Peishan Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peishan Hu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaojian Wu

    Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    5 shared publications
  • Feng Gao

    Department of Colorectal Surgery, Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, China

    3 shared publications
  • Xinxin Huang

    Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou 510630, China

    3 shared publications
  • Chong Chen

    Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou 510630, China

    2 shared publications
  • Dongwen Chen

    Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou 510630, China

    2 shared publications
  • Du Cai

    Department of General Surgery (Department of Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Clinical Research Center for Digestive Diseases, Guangzhou, Guangdong, China

    2 shared publications

Latest Publications

  • Open Access

    Multi-omics driven immune classification of colorectal cancer: Implications for immunotherapy efficacy prediction and enhancement with WNT signaling inhibition

    by Chuling Hu, Du Cai, Weiqiang You, Zhengran Zhou, Junwei Liu, Cheng-Hang Li, Min-Yi Lv, Bao-Wen Gai, Chong Chen, Xinxin Huang, et al.


  • Open Access

    Lactylation of SLC26A3 in the acidic tumor microenvironment promotes malignant progression of colorectal carcinoma

    by Chong Chen, Du Cai, Xuanhui Liu, Yifan Zheng, Xinxin Huang, Dongwen Chen, Jiawei Cai, Yiran Bie, Zhengran Zhou, Chuling Hu, et al.

    The acidic tumor microenvironment provides the energy that drives the development of malignant tumors. High concentrations of lactic acid and H + are key features of the acidic tumor microenvironment, and lactylation has gradually been shown to play a significant role in tumor progression. The expression of solute carrier family 26 member 3 (SLC26A3) is closely related to the occurrence and development of colorectal cancer (CRC), but the specific molecular mechanisms remain unclear. We demonstrated that alterations in the acidic microenvironment and overexpression of SLC26A3 significantly inhibited CRC occurrence and progression in vivo. Our study indicates that SLC26A3 undergoes lactylation in the acidic tumor microenvironment, which decreases SLC26A3 stability and expression. SLC26A3 interacts with the RNA-binding proteins Hu antigen R (HuR) and CUG-binding protein 1 (CUGBP1). When SLC26A3 expression is reduced, its ability to bind to HuR/CUGBP1 is weakened. As a result, HuR and CUGBP1 more readily interact with a subset of oncogenic mRNAs, regulating their stability and influencing their expression, ultimately promoting malignant tumor progression. These findings highlight the role of SLC26A3 as a potential suppressor of CRC recurrence, drug resistance, and metastasis, providing new insights for improving the clinical treatment and prognosis of CRC.


  • Open Access

    Correction: Huang et al. Duodenal Adenocarcinoma Is Characterized by Acidity, High Infiltration of Macrophage, and Activated Linc01559–GRSF1 Axis. Biomedicines 2025, 13, 1611

    by Xinxin Huang, Ying Shi, Zekun Liu, Yihang Wu, Xiaotong Luo, Dongwen Chen, Zhengyu Wei, Chong Chen, Huaiqiang Ju, Xiaojian Wu, et al.


  • Open Access

    Fatty acid in the tumor microenvironment: Perspectives for immunotherapy

    by Ting Li, Yi-Ran Bie, Shan-Mei Chen, Yao Shang, Pei-Shan Hu


  • Open Access

    Duodenal Adenocarcinoma Is Characterized by Acidity, High Infiltration of Macrophage, and Activated Linc01559–GRSF1 Axis

    by Xinxin Huang, Ying Shi, Zekun Liu, Yihang Wu, Xiaotong Luo, Dongwen Chen, Zhengyu Wei, Chong Chen, Huaiqiang Ju, Xiaojian Wu, et al.

    Background: Duodenal adenocarcinoma (DA) is often insidious due to the low rate of early diagnosis and because the mechanisms that underlie its malignant progression are poorly understood. The tumor microenvironment (TME) plays a crucial regulatory role in promoting tumor malignancy. Hence, this study aimed to identify novel biomarkers for early diagnosis and potential therapeutic targets for DA. Methods: Surgical resection samples and normal tissues from DA patients were collected for RNA sequencing (RNA-seq). The characteristics of TME in DA patients were analyzed, and the differentially expressed long non-coding RNAs (lncRNA) were screened. Functional experiments were performed to verify the relationship between Linc01559, G-rich sequence binding factor 1 (GRSF1), and tumor malignant phenotype. Results: The present study revealed that DA exhibits a significantly upregulated expression of acidic environment markers and a high degree of macrophage infiltration. Further investigation revealed that macrophages upregulate the expression of the long noncoding RNA, Linc01559, in DA through the STAT3/c-MYC signaling pathway, thereby promoting malignant phenotypes such as invasion, metastasis, tumor stemness, and apoptosis. The interaction between GRSF1 and Linc01559 was subsequently confirmed using RNA pulldown-mass spectrometry. It was further revealed that Linc01559 promotes the malignant phenotype of duodenal cancer cells through its interaction with GRSF1. Conclusions: These findings demonstrate that the acidic microenvironment influences the phenotype of DA by regulating the Linc01559–GRSF1 axis. Therefore, these findings provide potential targets for the early detection and treatment of DA.


  • Open Access

    KRAS Inhibitors Are Potential Prophylaxis for Colorectal Cancer Metachronous Metastasis

    by Yaoyu Guo, Chuling Hu, Guojie Long, Du Cai, Zhaoliang Yu, Xingxing Huang, Zerong Cai, Peishan Hu, Yufeng Chen, Feng Gao, et al.

    Colorectal cancer (CRC) with KRAS mutation is prone to develop metachronous metastasis. However, effective measures for prediction and prevention of such clinical issue are currently unavailable. In this study, we confirmed that KRAS mutation is a risk factor for CRC metachronous metastasis through meta-analysis and public database analysis. Based on the ICGC-AGRO database, we have constructed a risk scoring model for predicting metachronous metastasis in KRAS-mutant CRC using machine learning, which was validated in public datasets. Furthermore, we discovered that KRAS inhibitors can effectively suppress the migration and invasion capabilities of high risk CRC cells by wound healing assay and transwell experiment, which was validated ex vivo and in vivo using organoids and splenic liver metastatic mouse model. Finally, RNA sequencing, RT-qPCR, and western blots have proven that KRAS inhibitors can suppress the epithelial-mesenchymal transition (EMT) and transforming growth factor beta (TGF-beta) signaling pathway in CRC. Collectively, our study suggests that KRAS inhibitors may inhibit the metastatic ability of CRC by suppressing EMT and the TGF-beta pathway, suggesting their potential for the prevention of metachronous metastasis in CRC with KRAS mutation.

  • PFKFB2 is a favorable prognostic biomarker for colorectal cancer by suppressing metastasis and tumor glycolysis

    by Furong Liu, Xiaoli Wei, Zhanhong Chen, Yanxing Chen, Peishan Hu, Ying Jin

    Purpose This study was to investigate the biological effect of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2) in colorectal cancer (CRC). Methods PFKFB2 was selected by metabolism polymerase chain reaction (PCR) array from CRC cells under alkaline culture medium (pH 7.4) and acidic culture medium (pH 6.8). The expression of PFKFB2 mRNA and protein was detected by quantitative real-time PCR and immunohistochemistry in 70 paired fresh and 268 paired paraffin-embedded human CRC tissues, respectively, and then the prognostic value of PFKFB2 was investigated. The effects of PFKFB2 on CRC cells were also verified in vitro, which were through detecting the change of migration, invasion, sphere formation, proliferation, colony formation, and extracellular acidification rate of CRC cells after PFKFB2 knockdown in alkaline culture medium (pH 7.4) and overexpression in acidic culture medium (pH 6.8). Results PFKFB2 expression was downregulated in acidic culture medium (pH 6.8). In addition, we found PFKFB2 expression decreased in human CRC tissues compared with the adjacent normal tissues. Furthermore, the OS and DFS rate of CRC patients with low PFKFB2 expression was significantly shorter than those of patients with high PFKFB2 expression. Multivariate analysis indicated that low PFKFB2 expression was an independent prognostic factor for both OS and DFS in CRC patients. Moreover, the abilities of migration, invasion, spheroidizing ability, proliferation, and colony formation of CRC cells were significantly increased after depletion of PFKFB2 in alkaline culture medium (pH 7.4) and decreased after overexpression of PFKFB2 in acidic culture medium (pH 6.8) in vitro. Epithelial–mesenchymal transition (EMT) pathway was found and verified involved in the PFKFB2-mediated regulation of metastatic function in CRC cells. Further, glycolysis of CRC cells was significantly elevated after knockdown of PFKFB2 in alkaline culture medium (pH 7.4) and decreased after overexpression of PFKFB2 in acidic culture medium (pH 6.8). Conclusion PFKFB2 expression is downregulated in CRC tissues and associated with worse survival for CRC patients. PFKFB2 could inhibit metastasis and the malignant progression of CRC cells by suppressing EMT and glycolysis.